Molecular Drug Targets and Structure Based Drug Design: A Holistic Approach

Overview

Journal Bioinformation

Specialty Biology

Date 2007 Jun 29

PMID 17597912

Citations 20

Authors

Shailza Singh

Balwant Kumar Malik

Durlabh Kumar Sharma

Affiliations

Soon will be listed here.

Abstract

Access to the complete human genome sequence as well as to the complete sequences of pathogenic organisms provides information that can result in an avalanche of therapeutic targets. Structure-based design is one of the first techniques to be used in drug design. Structure based design refers specifically to finding and complementing the 3D structure (binding and/or active site) of a target molecule such as a receptor protein. The aim of this review is to give an outline of studies in the field of structure based drug design that has helped in the discovery process of new drugs. The emphasis will be on comparative/homology modeling.

Citing Articles

Investigation the effect of the aqueous extract of (L.) on visceral leishmaniasis.

Ghusoon A, Buthaina A Trop Parasitol. 2024; 14(2):84-94.

PMID: 39411680 PMC: 11473012. DOI: 10.4103/tp.tp_1_24.

Developing phytocompound-based new drugs against multi-drug-resistant .

Shuvo M, Halder S, Alam N, Himel M, Shil A R Soc Open Sci. 2024; 11(7):231475.

PMID: 39050719 PMC: 11265916. DOI: 10.1098/rsos.231475.

Decrypting the molecular basis of cellular drug phenotypes by dose-resolved expression proteomics.

Eckert S, Berner N, Kramer K, Schneider A, Muller J, Lechner S Nat Biotechnol. 2024; .

PMID: 38714896 DOI: 10.1038/s41587-024-02218-y.

Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management.

Agu P, Afiukwa C, Orji O, Ezeh E, Ofoke I, Ogbu C Sci Rep. 2023; 13(1):13398.

PMID: 37592012 PMC: 10435576. DOI: 10.1038/s41598-023-40160-2.

Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies.

Toigo L, Dos Santos Teodoro E, Guidi A, Gancedo N, Petruco M, Melo E Daru. 2023; 31(1):51-68.

PMID: 37195402 PMC: 10191091. DOI: 10.1007/s40199-023-00461-3.

References

Koga H, Itoh A, Murayama S, SUZUE S, IRIKURA T . Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem. 1980; 23(12):1358-63. DOI: 10.1021/jm00186a014. View

Anderson A . The process of structure-based drug design. Chem Biol. 2003; 10(9):787-97. DOI: 10.1016/j.chembiol.2003.09.002. View

Wlodawer A, Vondrasek J . Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu Rev Biophys Biomol Struct. 1998; 27:249-84. DOI: 10.1146/annurev.biophys.27.1.249. View

Vankayalapati H, Bearss D, Saldanha J, Munoz R, Rojanala S, Von Hoff D . Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther. 2003; 2(3):283-94. View

Ecker , Griffey . RNA as a small-molecule drug target: doubling the value of genomics. Drug Discov Today. 1999; 4(9):420-429. DOI: 10.1016/s1359-6446(99)01389-6. View

Cacace A, Banks M, Spicer T, Civoli F, Watson J . An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors. Drug Discov Today. 2003; 8(17):785-92. DOI: 10.1016/s1359-6446(03)02809-5. View

Goodford P, St-Louis J, Wootton R . The interaction of human haemoglobin with allosteric effectors as a model for drug-receptor interactions. Br J Pharmacol. 1980; 68(4):741-8. PMC: 2044221. DOI: 10.1111/j.1476-5381.1980.tb10867.x. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Blundell T . Structure-based drug design. Nature. 1996; 384(6604 Suppl):23-6. DOI: 10.1038/384023a0. View

10.

Pellecchia M, Sem D, Wuthrich K . NMR in drug discovery. Nat Rev Drug Discov. 2002; 1(3):211-9. DOI: 10.1038/nrd748. View

11.

Glen R, Martin G, Hill A, Hyde R, Woollard P, Salmon J . Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties. J Med Chem. 1995; 38(18):3566-80. DOI: 10.1021/jm00018a016. View

12.

Greer J, Erickson J, Baldwin J, Varney M . Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem. 1994; 37(8):1035-54. DOI: 10.1021/jm00034a001. View

13.

Blundell T, Sibanda B, Pearl L . Three-dimensional structure, specificity and catalytic mechanism of renin. Nature. 1983; 304(5923):273-5. DOI: 10.1038/304273a0. View

14.

Campbell S . Science, art and drug discovery: a personal perspective. Clin Sci (Lond). 2000; 99(4):255-60. View

15.

Huynen M, Diaz-Lazcoz Y, Bork P . Differential genome display. Trends Genet. 1997; 13(10):389-90. DOI: 10.1016/s0168-9525(97)01255-9. View

16.

Haq I . Thermodynamics of drug-DNA interactions. Arch Biochem Biophys. 2002; 403(1):1-15. DOI: 10.1016/S0003-9861(02)00202-3. View

17.

Keenan R, Weinstock J, Finkelstein J, Franz R, Gaitanopoulos D, Girard G . Potent nonpeptide angiotensin II receptor antagonists. 2. 1-(Carboxybenzyl)imidazole-5-acrylic acids. J Med Chem. 1993; 36(13):1880-92. DOI: 10.1021/jm00065a011. View

18.

Drews J . Drug discovery: a historical perspective. Science. 2000; 287(5460):1960-4. DOI: 10.1126/science.287.5460.1960. View

19.

Enyedy I, Lee S, Kuo A, Dickson R, Lin C, Wang S . Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J Med Chem. 2001; 44(9):1349-55. DOI: 10.1021/jm000395x. View

20.

Kawakami Y, Inoue A, Kawai T, Wakita M, Sugimoto H, Hopfinger A . The rationale for E2020 as a potent acetylcholinesterase inhibitor. Bioorg Med Chem. 1996; 4(9):1429-46. DOI: 10.1016/0968-0896(96)00137-x. View